{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:40:46Z","timestamp":1790793646714,"version":"4.1.0"},"reference-count":263,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":151,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC2-11157"],"award-info":[{"award-number":["DISC2-11157"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC2-13505"],"award-info":[{"award-number":["DISC2-13505"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC2COVID19-12020"],"award-info":[{"award-number":["DISC2COVID19-12020"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["TRAN1-08533"],"award-info":[{"award-number":["TRAN1-08533"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["TRAN1-12250"],"award-info":[{"award-number":["TRAN1-12250"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001558","name":"Concern Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001880","name":"STOP CANCER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP2 CA196335"],"award-info":[{"award-number":["DP2 CA196335"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015591","name":"The Rose Hills Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015591","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009020","name":"USC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009020","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Stem Cell"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.stem.2023.02.009","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T13:01:25Z","timestamp":1679403685000},"page":"592-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Advancing cell-based cancer immunotherapy through stem cell engineering"],"prefix":"10.1016","volume":"30","author":[{"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary Spencer","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.stem.2023.02.009_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.1174935","article-title":"Medicine. A history lesson for stem cells","volume":"324","author":"Wilson","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.stem.2023.02.009_bib2","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1158\/0008-5472.CAN-16-1311","article-title":"Allogeneic stem cell transplantation: A historical and scientific overview","volume":"76","author":"Singh","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.stem.2023.02.009_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.stem.2023.02.009_bib4","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.stem.2023.02.009_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/PPO.0000000000000162","article-title":"Tumor-infiltrating lymphocyte therapy: addressing prevailing questions","volume":"21","author":"Radvanyi","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.stem.2023.02.009_bib6","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1172\/JCI32446","article-title":"Adoptive T\u00a0cell therapy for cancer in the clinic","volume":"117","author":"June","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.stem.2023.02.009_bib7","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1200\/EDBK_279151","article-title":"Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities","volume":"40","author":"Kansagra","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. B."},{"key":"10.1016\/j.stem.2023.02.009_bib8","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","article-title":"Chimeric antigen receptors T\u00a0cell therapy in solid tumor: challenges and clinical applications","volume":"8","author":"Mirzaei","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing chimeric antigen receptor T\u00a0cells: issues and challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2023.02.009_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4049\/jimmunol.1701155","article-title":"Chimeric antigen receptor T\u00a0cell therapy: challenges to bench-to-bedside efficacy","volume":"200","author":"Srivastava","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib11","doi-asserted-by":"crossref","first-page":"90521","DOI":"10.18632\/oncotarget.19361","article-title":"Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities","volume":"8","author":"Xia","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.stem.2023.02.009_bib12","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib13","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T cell therapy for lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.stem.2015.03.011","article-title":"New cell sources for T\u00a0cell engineering and adoptive immunotherapy","volume":"16","author":"Themeli","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib16","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T\u00a0cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib17","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T\u00a0cell transition in CAR T\u00a0cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib18","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T\u00a0cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib19","doi-asserted-by":"crossref","first-page":"e150807","DOI":"10.1172\/JCI150807","article-title":"CAR T-cell manufacturing from naive\/stem memory T-lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.stem.2023.02.009_bib20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T\u00a0cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.stem.2023.02.009_bib22","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.stem.2023.02.009_bib23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib24","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.stem.2023.02.009_bib25","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1182\/blood-2018-99-110194","article-title":"A Phase 1 study with point-of-care manufacturing of dual targeted, tandem anti-CD19, anti-CD20 chimeric antigen receptor modified T (CAR-T) cells for relapsed, refractory, non-Hodgkin lymphoma","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib26","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"132","author":"Benjamin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.stem.2023.02.009_bib28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.stem.2023.02.009_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/bloodadvances.2017011254","article-title":"Improving T-cell expansion and function for adoptive T-cell therapy using ex\u00a0vivo treatment with PI3Kd inhibitors and VIP antagonists","volume":"2","author":"Petersen","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.stem.2023.02.009_bib31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T\u00a0cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.stem.2023.02.009_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/antib11020031","article-title":"Advances in chimeric antigen receptor (CAR) T-cell therapies for the treatment of primary brain tumors","volume":"11","author":"Mount","year":"2022","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.stem.2023.02.009_bib33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T\u00a0cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T\u00a0cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.stem.2023.02.009_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40259-017-0247-0","article-title":"Next-generation chimeric antigen receptor T-cell therapy: going off the shelf","volume":"31","author":"Ruella","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.stem.2023.02.009_bib36","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T\u00a0cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.stem.2023.02.009_bib37","doi-asserted-by":"crossref","first-page":"583716","DOI":"10.3389\/fimmu.2020.583716","article-title":"Off-the-shelf allogeneic T\u00a0cell therapies for cancer: opportunities and challenges using naturally occurring \u201cuniversal\u201d donor T\u00a0cells","volume":"11","author":"Perez","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib38","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T\u00a0cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.stem.2023.02.009_bib39","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1182\/blood-2011-11-389304","article-title":"Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Chaidos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib40","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.stem.2023.02.009_bib41","doi-asserted-by":"crossref","first-page":"eaat8410","DOI":"10.1126\/scitranslmed.aat8410","article-title":"Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells","volume":"10","author":"Tugues","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib42","doi-asserted-by":"crossref","first-page":"897750","DOI":"10.3389\/fmed.2022.897750","article-title":"Adoptive immunotherapy with engineered iNKT cells to target cancer cells and the suppressive microenvironment","volume":"9","author":"Delfanti","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.stem.2023.02.009_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12272-019-01139-8","article-title":"Roles of NKT cells in cancer immunotherapy","volume":"42","author":"Bae","year":"2019","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.stem.2023.02.009_bib44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.immuni.2018.03.009","article-title":"Unconventional T\u00a0cell targets for cancer immunotherapy","volume":"48","author":"Godfrey","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.stem.2023.02.009_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fimmu.2020.00060","article-title":"Targeting natural killer cells for tumor immunotherapy","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib46","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ymthe.2022.11.019","article-title":"Mucosal-associated invariant T\u00a0cells for cancer immunotherapy","volume":"31","author":"Li","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.stem.2023.02.009_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tips.2020.11.004","article-title":"Innate and innate-like cells: the future of chimeric antigen receptor (CAR) cell therapy","volume":"42","author":"Cort\u00e9s-Selva","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.stem.2023.02.009_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.stem.2023.02.009_bib49","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","article-title":"Genetic engineering of T\u00a0cells for immunotherapy","volume":"22","author":"Ellis","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.stem.2023.02.009_bib50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The emerging landscape of immune cell therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1399-3046.2004.00231.x","article-title":"Basic mechanisms of humoral rejection","volume":"9","author":"Cascalho","year":"2005","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.stem.2023.02.009_bib52","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.smim.2011.08.021","article-title":"Humoral immunity and antibody-mediated rejection in solid organ transplantation","volume":"23","author":"Montgomery","year":"2011","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib53","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/tan.12564","article-title":"A future with less HLA: potential clinical applications of HLA-universal cells","volume":"85","author":"Figueiredo","year":"2015","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.stem.2023.02.009_bib54","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.stem.2023.02.009_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123497","article-title":"Development of stem cell-derived immune cells for off-the-shelf cancer immunotherapies","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.stem.2023.02.009_bib56","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.trecan.2021.08.004","article-title":"Engineering stem cells for cancer immunotherapy","volume":"7","author":"Li","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.stem.2023.02.009_bib57","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/stem.2754","article-title":"Concise review: human pluripotent stem cells to produce cell-based cancer immunotherapy","volume":"36","author":"Zhu","year":"2018","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2023.02.009_bib58","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood-2004-04-1649","article-title":"Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential","volume":"105","author":"Vodyanik","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib59","doi-asserted-by":"crossref","first-page":"10716","DOI":"10.1073\/pnas.191362598","article-title":"Hematopoietic colony-forming cells derived from human embryonic stem cells","volume":"98","author":"Kaufman","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.stem.2023.02.009_bib60","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nprot.2008.42","article-title":"A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies","volume":"3","author":"Ng","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.stem.2023.02.009_bib61","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.celrep.2012.11.003","article-title":"T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures","volume":"2","author":"Kennedy","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.stem.2023.02.009_bib62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.stemcr.2016.01.005","article-title":"Cellular adjuvant properties, direct cytotoxicity of re-differentiated V\u03b124 invariant NKT-like cells from human induced pluripotent stem cells","volume":"6","author":"Kitayama","year":"2016","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.stem.2023.02.009_bib63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-4939-8938-6_3","article-title":"Generation of antigen-specific T\u00a0cells from human induced pluripotent stem cells","volume":"1899","author":"Nishimura","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.stem.2023.02.009_bib64","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","article-title":"Generation of rejuvenated antigen-specific T\u00a0cells by reprogramming to pluripotency and redifferentiation","volume":"12","author":"Nishimura","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2012.12.006","article-title":"Regeneration of human tumor antigen-specific T\u00a0cells from iPSCs derived from mature CD8(+) T\u00a0cells","volume":"12","author":"Vizcardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib66","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.stem.2013.03.001","article-title":"Expansion of functional human mucosal-associated invariant T\u00a0cells via reprogramming to pluripotency and redifferentiation","volume":"12","author":"Wakao","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib67","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.stemcr.2017.10.020","article-title":"Generation of \u201coff-the-shelf\u201d natural killer cells from peripheral blood cell-derived induced pluripotent stem cells","volume":"9","author":"Zeng","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.stem.2023.02.009_bib68","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T\u00a0cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib69","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T\u00a0cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib70","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19\u201328z CAR T\u00a0cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib71","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T\u00a0cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib72","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.stem.2023.02.009_bib73","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1\u2013specific TCR\u2013engineered T\u00a0cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib74","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","article-title":"TCR engineered T\u00a0cells for solid tumor immunotherapy","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.stem.2023.02.009_bib75","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.stem.2023.02.009_bib76","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (Transcend NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.stem.2023.02.009_bib77","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.hemonc.2021.09.004","article-title":"Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: what is the evidence?","volume":"15","author":"Kharfan-Dabaja","year":"2022","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"10.1016\/j.stem.2023.02.009_bib78","doi-asserted-by":"crossref","first-page":"100449","DOI":"10.1016\/j.xcrm.2021.100449","article-title":"Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell reports","volume":"2","author":"Li","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib79","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.4237","article-title":"Generation of mature T\u00a0cells from human hematopoietic stem and progenitor cells in artificial thymic organoids","volume":"14","author":"Seet","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.stem.2023.02.009_bib80","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.stem.2018.12.011","article-title":"Organoid-induced differentiation of conventional T\u00a0cells from human pluripotent stem cells","volume":"24","author":"Montel-Hagen","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib81","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/stem.2115","article-title":"In\u00a0vitro T-cell generation from adult, embryonic, and induced pluripotent stem cells: many roads to one destination","volume":"33","author":"Smith","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2023.02.009_bib82","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0092-8674(00)81368-9","article-title":"An activated form of Notch influences the choice between CD4 and CD8 T\u00a0cell lineages","volume":"87","author":"Robey","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib83","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.immunol.17.1.283","article-title":"Regulation of T\u00a0cell fate by Notch","volume":"17","author":"Robey","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib84","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/35006664","article-title":"The duration of antigen receptor signalling determines CD4+ versus CD8+ T-cell lineage fate","volume":"404","author":"Yasutomo","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.stem.2023.02.009_bib85","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib86","doi-asserted-by":"crossref","first-page":"561553","DOI":"10.3389\/fimmu.2020.561553","article-title":"Umbilical cord blood and iPSC-derived natural killer cells demonstrate key differences in cytotoxic activity and KIR profiles","volume":"11","author":"Goldenson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib87","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/stem.2230","article-title":"Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer","volume":"34","author":"Hermanson","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2023.02.009_bib88","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.stem.2023.02.009_bib89","doi-asserted-by":"crossref","first-page":"e1017701","DOI":"10.1080\/2162402X.2015.1017701","article-title":"Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer","volume":"4","author":"Cany","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.stem.2023.02.009_bib90","doi-asserted-by":"crossref","first-page":"eaaz5618","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in\u00a0vivo tumor control in concert with T\u00a0cells and anti\u2013PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib91","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.smim.2017.07.009","article-title":"NK cell-based immunotherapy for cancer","volume":"31","author":"Fang","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib92","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.stem.2023.02.009_bib93","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.4049\/jimmunol.175.8.5095","article-title":"Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity","volume":"175","author":"Woll","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib94","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4939-9728-2_12","article-title":"An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells","volume":"2048","author":"Zhu","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.stem.2023.02.009_bib95","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in\u00a0vivo persistence and enhances anti-tumor activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib96","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib97","first-page":"2064","article-title":"Role of NKG2D and its ligands in cancer immunotherapy","volume":"9","author":"Liu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.stem.2023.02.009_bib98","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","article-title":"Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value","volume":"110","author":"Ruggeri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib99","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer immunotherapy based on natural killer cells: current progress and new opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib101","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib102","doi-asserted-by":"crossref","first-page":"575609","DOI":"10.3389\/fimmu.2020.575609","article-title":"Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy","volume":"11","author":"Alfarra","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2013.00409","article-title":"NKT cells as an ideal anti-tumor immunotherapeutic","volume":"4","author":"Fujii","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib104","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13287-022-02787-2","article-title":"Development of off\u00a0\u2013 the\u00a0\u2013 shelf hematopoietic stem cell\u00a0\u2013 engineered invariant natural killer T\u00a0cells for COVID - 19 therapeutic intervention","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.stem.2023.02.009_bib105","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","article-title":"Development of hematopoietic stem cell-engineered invariant natural killer T\u00a0cell therapy for cancer","volume":"25","author":"Zhu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib106","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1073\/pnas.1424877112","article-title":"Genetic engineering of hematopoietic stem cells to generate invariant natural killer T\u00a0cells","volume":"112","author":"Smith","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.stem.2023.02.009_bib107","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-0716-0207-2_16","article-title":"Reprogramming of MAIT cells to pluripotency and redifferentiation","volume":"2098","author":"Wakao","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.stem.2023.02.009_bib108","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.4161\/cc.25706","article-title":"Toward the realization of cell therapy: the advent of MAIT cells from iPSCs","volume":"12","author":"Wakao","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.stem.2023.02.009_bib109","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-0716-1775-5_4","article-title":"Methods for studying mouse and human invariant natural killer T\u00a0cells","volume":"2388","author":"Zhou","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.stem.2023.02.009_bib110","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.scr.2018.04.016","article-title":"Efficient production of erythroid, megakaryocytic and myeloid cells, using single cell-derived iPSC colony differentiation","volume":"29","author":"Hansen","year":"2018","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.stem.2023.02.009_bib111","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/stem.3095","article-title":"Induced pluripotent stem cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy","volume":"38","author":"Horton","year":"2020","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2023.02.009_bib112","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3389\/fimmu.2017.01935","article-title":"Directed differentiation of human induced pluripotent stem cells into dendritic cells displaying tolerogenic properties and resembling the CD141(+) subset","volume":"8","author":"Sachamitr","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib113","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.stem.2023.02.009_bib114","doi-asserted-by":"crossref","first-page":"e8208","DOI":"10.1371\/journal.pone.0008208","article-title":"Engineering antigen-specific T\u00a0cells from genetically modified human hematopoietic stem cells in immunodeficient mice","volume":"4","author":"Kitchen","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.stem.2023.02.009_bib115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood-2005-11-4388","article-title":"Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus\/liver and CD34+ cell transplantation","volume":"108","author":"Lan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib116","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/nm1431","article-title":"Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1","volume":"12","author":"Melkus","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib117","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1634\/stemcells.2006-0814","article-title":"A novel culture technique for human embryonic stem cells using porous membranes","volume":"25","author":"Kim","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2023.02.009_bib118","first-page":"145","article-title":"Feeder Cell Sources and Feeder-Free Methods for Human iPS Cell Culture BT\u00a0\u2013 Interface Oral Health Science 2014","author":"Yu","year":"2015"},{"key":"10.1016\/j.stem.2023.02.009_bib119","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10815-010-9408-5","article-title":"Derivation and long-term culture of human parthenogenetic embryonic stem cells using human foreskin feeders","volume":"27","author":"Lu","year":"2010","journal-title":"J.\u00a0Assist. Reprod. Genet."},{"key":"10.1016\/j.stem.2023.02.009_bib120","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1089\/scd.2010.0496","article-title":"Human feeder cells can support the undifferentiated growth of human and mouse embryonic stem cells using their own basic fibroblast growth factors","volume":"20","author":"Park","year":"2011","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.stem.2023.02.009_bib121","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/humrep\/dep232","article-title":"Immortalized human skin fibroblast feeder cells support growth and maintenance of both human embryonic and induced pluripotent stem cells","volume":"24","author":"Unger","year":"2009","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.stem.2023.02.009_bib122","doi-asserted-by":"crossref","first-page":"875059","DOI":"10.1155\/2012\/875059","article-title":"The effect of human and mouse fibroblast feeder cells on cardiac differentiation of human pluripotent stem cells","volume":"2012","author":"Pekkanen-Mattila","year":"2012","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.stem.2023.02.009_bib123","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1189\/jlb.1TA0214-121RR","article-title":"Technical advance: ascorbic acid induces development of double-positive T\u00a0cells from human hematopoietic stem cells in the absence of stromal cells","volume":"96","author":"Huijskens","year":"2014","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.stem.2023.02.009_bib124","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nmeth.4258","article-title":"Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1","volume":"14","author":"Shukla","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.stem.2023.02.009_bib125","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41467-020-20658-3","article-title":"A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy","volume":"12","author":"Iriguchi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.stem.2023.02.009_bib126","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.4049\/jimmunol.177.9.6548","article-title":"Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes","volume":"177","author":"Johnson","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib127","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.4049\/jimmunol.175.9.5799","article-title":"Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR","volume":"175","author":"Cohen","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-08-1638","article-title":"Characterization of genetically modified T-cell receptors that recognize the CEA:691\u2013699 peptide in the context of HLA-A2.1 on human colorectal cancer cells","volume":"15","author":"Parkhurst","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.stem.2023.02.009_bib129","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nbt1070","article-title":"Directed evolution of human T-cell receptors with picomolar affinities by phage display","volume":"23","author":"Li","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.stem.2023.02.009_bib130","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/nm.1779","article-title":"Control of HIV-1 immune escape by CD8 T\u00a0cells expressing enhanced T-cell receptor","volume":"14","author":"Varela-Rohena","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib131","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.hoc.2017.06.012","article-title":"Hematopoietic stem cell approaches to cancer","volume":"31","author":"Adair","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.stem.2023.02.009_bib132","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.stem.2023.02.009_bib133","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1073\/pnas.0500600102","article-title":"Long-term in\u00a0vivo provision of antigen-specific T\u00a0cell immunity by programming hematopoietic stem cells","volume":"102","author":"Yang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.stem.2023.02.009_bib134","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1073\/pnas.092154599","article-title":"Generation of functional antigen-specific T\u00a0cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAS in hematopoietic precursor cells","volume":"99","author":"Yang","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.stem.2023.02.009_bib135","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.stem.2023.02.009_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T\u00a0cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib137","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1038\/s41467-019-13007-6","article-title":"Highly efficient multiplex human T\u00a0cell engineering without double-strand breaks using Cas9 base editors","volume":"10","author":"Webber","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.stem.2023.02.009_bib138","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T\u00a0cells, and universal CAR T\u00a0cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.stem.2023.02.009_bib139","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib140","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib141","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","article-title":"CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells","volume":"11","author":"Zhang","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib142","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/mt.2015.71","article-title":"Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma","volume":"23","author":"Beane","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.stem.2023.02.009_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0352-x","article-title":"Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering","volume":"51","author":"Jang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib144","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1158\/0008-5472.CAN-18-0030","article-title":"CRISPR\/Cas9-mediated knockout of DGK improves antitumor activities of human T\u00a0cells","volume":"78","author":"Jung","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.stem.2023.02.009_bib145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.stem.2023.02.009_bib146","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nm.2700","article-title":"Editing T\u00a0cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer","volume":"18","author":"Provasi","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib147","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T\u00a0cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.stem.2023.02.009_bib148","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.gene.2017.09.010","article-title":"CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes","volume":"636","author":"Shi","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.stem.2023.02.009_bib149","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/7651_2021_352","article-title":"CRISPR\/Cas9 ribonucleoprotein complex-mediated efficient B2M knockout in human induced pluripotent stem cells (iPSCs)","volume":"2454","author":"Thongsin","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.stem.2023.02.009_bib150","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.stem.2023.02.009_bib151","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T\u00a0cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.stem.2023.02.009_bib152","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nprot.2017.016","article-title":"Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening","volume":"12","author":"Joung","year":"2017","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.stem.2023.02.009_bib153","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/s41467-022-29205-8","article-title":"CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T\u00a0cell-mediated cytotoxicity","volume":"13","author":"Joung","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.stem.2023.02.009_bib154","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T\u00a0cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.stem.2023.02.009_bib155","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1038\/s41467-018-07901-8","article-title":"Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities","volume":"9","author":"Sanson","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.stem.2023.02.009_bib156","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","article-title":"Genome-wide CRISPR screens in primary human T\u00a0cells reveal key regulators of immune function","volume":"175","author":"Shifrut","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib157","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/2159-8290.CD-20-1243","article-title":"Crispr screening of car T\u00a0cells and cancer stem cells reveals critical dependencies for cell-based therapies","volume":"11","author":"Wang","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.stem.2023.02.009_bib158","first-page":"419","article-title":"Engineering T Cells Using CRISPR\/Cas9 for Cancer Therapy","author":"Zhang","year":"2020"},{"key":"10.1016\/j.stem.2023.02.009_bib159","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.stem.2023.02.009_bib160","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib161","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1172\/JCI59535","article-title":"IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity","volume":"122","author":"Liu","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.stem.2023.02.009_bib162","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in\u00a0vivo persistence and antitumor activity against neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.stem.2023.02.009_bib163","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/intimm\/13.2.193","article-title":"HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition","volume":"13","author":"Riteau","year":"2001","journal-title":"Int. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib164","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","article-title":"HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A","volume":"95","author":"Lee","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.stem.2023.02.009_bib165","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T\u00a0cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.stem.2023.02.009_bib166","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fmed.2018.00118","article-title":"Considering cell therapy product \u201cgood manufacturing practice\u201d status","volume":"5","author":"Bedford","year":"2018","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.stem.2023.02.009_bib167","first-page":"243","article-title":"Cell therapy: cGMP facilities and manufacturing","volume":"2","author":"Giancola","year":"2012","journal-title":"Muscles Ligaments Tendons J."},{"key":"10.1016\/j.stem.2023.02.009_bib168","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5966\/sctm.2014-0202","article-title":"Concise review: making and using clinically compliant pluripotent stem cell lines","volume":"4","author":"Carpenter","year":"2015","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib169","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nbt0709-606","article-title":"Developing safe therapies from human pluripotent stem cells","volume":"27","author":"Carpenter","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.stem.2023.02.009_bib170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5966\/sctm.2012-0149","article-title":"Meeting report: using stem cells for biological and therapeutics discovery in mental illness, April 2012","volume":"2","author":"Panchision","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib171","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5966\/sctm.2013-0042","article-title":"Pluripotent stem cells in translation: a Food and Drug Administration-National Institutes of Health collaboration","volume":"2","author":"Kleitman","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib172","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5966\/sctm.2012-0018","article-title":"Translation of stem cell research: points to consider in designing preclinical animal studies","volume":"1","author":"Frey-Vasconcells","year":"2012","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib173","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.stem.2023.02.009_bib174","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.3390\/cancers14092266","article-title":"Engineering induced pluripotent stem cells for cancer immunotherapy","volume":"14","author":"Zhou","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.stem.2023.02.009_bib175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/cells11020269","article-title":"Advances in allogeneic cancer cell therapy and future perspectives on \u201cOff-the-shelf\u201d T\u00a0cell therapy using iPSC technology and gene editing","volume":"11","author":"Furukawa","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.stem.2023.02.009_bib176","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.stem.2020.09.014","article-title":"Pluripotent stem cell-based cell therapy-promise and challenges","volume":"27","author":"Yamanaka","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib177","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.stem.2023.02.009_bib178","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jcyt.2019.10.001","article-title":"Tumorigenicity assessment of cell therapy products: the need for global consensus and points to consider","volume":"21","author":"Sato","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2023.02.009_bib179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3897\/compcytogen.v7i1.4431","article-title":"Karyotype asymmetry: again, how to measure and what to measure?","volume":"7","author":"Peruzzi","year":"2013","journal-title":"Comp. Cytogenet."},{"key":"10.1016\/j.stem.2023.02.009_bib180","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2010.06.003","article-title":"Generation of induced pluripotent stem cells from human terminally differentiated circulating T\u00a0cells","volume":"7","author":"Seki","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib181","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature05934","article-title":"Generation of germline-competent induced pluripotent stem cells","volume":"448","author":"Okita","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.stem.2023.02.009_bib182","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.1128\/JVI.74.14.6564-6569.2000","article-title":"A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression","volume":"74","author":"Li","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.stem.2023.02.009_bib183","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.1172482","article-title":"Human induced pluripotent stem cells free of vector and transgene sequences","volume":"324","author":"Yu","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.stem.2023.02.009_bib184","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.omtm.2021.03.002","article-title":"Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy","volume":"21","author":"Mashima","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.stem.2023.02.009_bib185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/CIRCRESAHA.114.305495","article-title":"Allogeneic cell therapy: a new paradigm in therapeutics","volume":"116","author":"Karantalis","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.stem.2023.02.009_bib186","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/35077251","article-title":"Haematopoietic cell transplantation as immunotherapy","volume":"411","author":"Appelbaum","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.stem.2023.02.009_bib187","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","article-title":"Current concepts and advances in graft-versus-host disease immunology","volume":"39","author":"Hill","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib188","doi-asserted-by":"crossref","first-page":"100792","DOI":"10.1016\/j.blre.2020.100792","article-title":"Graft-versus-host disease prophylaxis: pathophysiology-based review on current approaches and future directions","volume":"48","author":"Martinez-Cibrian","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.stem.2023.02.009_bib189","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.stem.2023.02.009_bib190","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/sctm.19-0423","article-title":"Killers at the crossroads: the use of innate immune cells in adoptive cellular therapy of cancer","volume":"9","author":"Sabry","year":"2020","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib191","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1083-8791(03)00108-3","article-title":"Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T\u00a0cells","volume":"9","author":"Lan","year":"2003","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"10.1016\/j.stem.2023.02.009_bib192","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.bmt.1704165","article-title":"Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors","volume":"32","author":"Yamasaki","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.stem.2023.02.009_bib193","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/ajt.14208","article-title":"Infection in organ transplantation","volume":"17","author":"Fishman","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.stem.2023.02.009_bib194","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.anclin.2017.04.001","article-title":"Overview of immunosuppressive therapy in solid organ transplantation","volume":"35","author":"Holt","year":"2017","journal-title":"Anesthesiol. Clin."},{"key":"10.1016\/j.stem.2023.02.009_bib195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1705866","article-title":"Eleven million donors in Bone Marrow Donors Worldwide! Time for reassessment?","volume":"41","author":"van Rood","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.stem.2023.02.009_bib196","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.humimm.2020.03.005","article-title":"Naming HLA diversity: a review of HLA nomenclature","volume":"82","author":"Hurley","year":"2021","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib197","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(05)67813-0","article-title":"Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching","volume":"366","author":"Taylor","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.stem.2023.02.009_bib198","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41577-019-0200-1","article-title":"Engineering universal cells that evade immune detection","volume":"19","author":"Lanza","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib199","doi-asserted-by":"crossref","first-page":"582939","DOI":"10.3389\/fimmu.2020.582939","article-title":"Macrophages in organ transplantation","volume":"11","author":"Ordikhani","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib200","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.stem.2023.02.009_bib201","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","article-title":"Generation of hypoimmunogenic T\u00a0cells from genetically engineered allogeneic human induced pluripotent stem cells","volume":"5","author":"Wang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.stem.2023.02.009_bib202","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-cell therapy in hematologic malignancies: A voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.stem.2023.02.009_bib203","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current progress in CAR-T cell therapy for hematological malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.stem.2023.02.009_bib204","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.stem.2023.02.009_bib205","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T\u00a0cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib206","doi-asserted-by":"crossref","first-page":"62730","DOI":"10.18632\/oncotarget.17528","article-title":"Driving better and safer HER2-specific CARs for cancer therapy","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.stem.2023.02.009_bib207","doi-asserted-by":"crossref","first-page":"LB-147","DOI":"10.1158\/1538-7445.AM2019-LB-147","article-title":"Abstract LB-147: Administration of HER2-CAR T\u00a0cells after lymphodepletion safely improves T\u00a0cell expansion and induces clinical responses in patients with advanced sarcomas","volume":"79","author":"Navai","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.stem.2023.02.009_bib208","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T\u00a0cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.stem.2023.02.009_bib209","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib210","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.stem.2023.02.009_bib211","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.stem.2023.02.009_bib212","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.stem.2023.02.009_bib213","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T\u00a0cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib214","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T\u00a0cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib215","doi-asserted-by":"crossref","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T\u00a0cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib216","doi-asserted-by":"crossref","first-page":"eabe2606","DOI":"10.1126\/scisignal.abe2606","article-title":"Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in\u00a0vivo function","volume":"14","author":"Salter","year":"2021","journal-title":"Sci. Signal."},{"key":"10.1016\/j.stem.2023.02.009_bib217","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T\u00a0cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib218","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/cancers13020312","article-title":"Engineering anti-tumor monoclonal antibodies and Fc receptors to enhance ADCC by human NK cells","volume":"13","author":"Dixon","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.stem.2023.02.009_bib219","doi-asserted-by":"crossref","first-page":"e0121788","DOI":"10.1371\/journal.pone.0121788","article-title":"Identification of an ADAM17 cleavage region in human CD16 (Fc\u03b3RIII) and the engineering of a non-cleavable version of the receptor in NK cells","volume":"10","author":"Jing","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.stem.2023.02.009_bib220","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib221","doi-asserted-by":"crossref","first-page":"8394960","DOI":"10.1155\/2016\/8394960","article-title":"Reprogramming of melanoma tumor-infiltrating lymphocytes to induced pluripotent stem cells","volume":"2016","author":"Saito","year":"2016","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.stem.2023.02.009_bib222","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","article-title":"Innate immune recognition of cancer","volume":"33","author":"Woo","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib223","doi-asserted-by":"crossref","first-page":"174803","DOI":"10.1016\/j.ejphar.2022.174803","article-title":"Gamma delta (\u03b3\u03b4) T\u00a0cells in cancer immunotherapy; where it comes from, where it will go?","volume":"919","author":"Deng","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.stem.2023.02.009_bib224","doi-asserted-by":"crossref","first-page":"e0216815","DOI":"10.1371\/journal.pone.0216815","article-title":"Derivation of mimetic \u03b3\u03b4 T\u00a0cells endowed with cancer recognition receptors from reprogrammed \u03b3\u03b4 T\u00a0cell","volume":"14","author":"Zeng","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.stem.2023.02.009_bib225","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","article-title":"Cellular networks controlling T\u00a0cell persistence in adoptive cell therapy","volume":"21","author":"Chan","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib226","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T\u00a0cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.stem.2023.02.009_bib227","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1042\/BST20150291","article-title":"Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.stem.2023.02.009_bib228","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/1566524023362519","article-title":"Critical role for IL-15 in innate immunity","volume":"2","author":"Ohteki","year":"2002","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.stem.2023.02.009_bib229","doi-asserted-by":"crossref","first-page":"e003441","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma Delta T\u00a0cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.stem.2023.02.009_bib230","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1182\/blood-2021-153258","article-title":"A bicistronic vector expressing CD16 and a membrane bound IL-15 construct in iPSC derived NK cells increased cytotoxicity and persistence","volume":"138","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib231","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1182\/blood-2021-146609","article-title":"Engineered interleukin-15 autocrine signaling invigorates anti-CD123 CAR-NK cells","volume":"138","author":"Christodoulou","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib232","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood-2021-150731","article-title":"Deletion of CISH and TGF\u03b2R2 in iPSC-derived NK cells promotes high cytotoxicity and enhances in\u00a0vivo tumor killing","volume":"138","author":"Gerew","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib233","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"C-Jun overexpression in CAR T\u00a0cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.stem.2023.02.009_bib234","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","article-title":"BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T\u00a0cells","volume":"22","author":"Seo","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib235","doi-asserted-by":"crossref","first-page":"20569","DOI":"10.1073\/pnas.1319061110","article-title":"Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells","volume":"110","author":"Koyanagi-Aoi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.stem.2023.02.009_bib236","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nbt1383","article-title":"Marked differences in differentiation propensity among human embryonic stem cell lines","volume":"26","author":"Osafune","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.stem.2023.02.009_bib237","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.stem.2012.05.005","article-title":"Induced pluripotent stem cells: past, present, and future","volume":"10","author":"Yamanaka","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib238","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.stem.2016.06.019","article-title":"Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity","volume":"19","author":"Nishizawa","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib239","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.stem.2014.07.002","article-title":"Systematic identification of culture conditions for induction and maintenance of naive human pluripotency","volume":"15","author":"Theunissen","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib240","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.cell.2014.08.029","article-title":"Resetting transcription factor control circuitry toward ground-state pluripotency in human","volume":"158","author":"Takashima","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib241","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41592-018-0104-1","article-title":"Reduced MEK inhibition preserves genomic stability in naive human embryonic stem cells","volume":"15","author":"Di Stefano","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.stem.2023.02.009_bib242","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.stem.2016.06.011","article-title":"Molecular criteria for defining the naive human pluripotent state","volume":"19","author":"Theunissen","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib243","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib244","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/cas.14374","article-title":"Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells","volume":"111","author":"Ueda","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.stem.2023.02.009_bib245","first-page":"A231.2","article-title":"380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors","volume":"8","author":"Hong","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.stem.2023.02.009_bib246","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2021-148654","article-title":"Off-the-shelf, multiplexed-engineered iPSC-derived NK cells mediate potent multi-antigen targeting of B-cell malignancies with reduced cytotoxicity against healthy B cells","volume":"138","author":"Cichocki","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.stem.2023.02.009_bib247","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101323","article-title":"An Alternative Cell Therapy for Cancers: Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer Cells","volume":"9","author":"Hsu","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.stem.2023.02.009_bib248","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/cmi.2012.17","article-title":"Generation of natural killer cells from hematopoietic stem cells in\u00a0vitro for immunotherapy","volume":"9","author":"Luevano","year":"2012","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib249","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.stem.2023.02.009_bib250","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nri3174","article-title":"Targeting natural killer cells and natural killer T\u00a0cells in cancer","volume":"12","author":"Vivier","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib251","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.stemcr.2015.07.011","article-title":"A safeguard system for induced pluripotent stem cell-derived rejuvenated T\u00a0cell therapy","volume":"5","author":"Ando","year":"2015","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.stem.2023.02.009_bib252","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.stem.2018.10.005","article-title":"Enhancing T\u00a0cell receptor stability in rejuvenated iPSC-derived T\u00a0cells improves their use in cancer immunotherapy","volume":"23","author":"Minagawa","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib253","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s11095-021-03067-z","article-title":"Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T\u00a0cell source for CAR-T cell development and off-the-shelf products","volume":"38","author":"Sadeqi Nezhad","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.stem.2023.02.009_bib254","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","article-title":"3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T\u00a0cells","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib255","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.stem.2022.06.014","article-title":"EZH1 repression generates mature iPSC-derived CAR T\u00a0cells with enhanced antitumor activity","volume":"29","author":"Jing","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2023.02.009_bib256","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02647.x","article-title":"Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T\u00a0cell-clonotypic monoclonal antibody, 6B11","volume":"122","author":"Montoya","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.stem.2023.02.009_bib257","doi-asserted-by":"crossref","first-page":"104859","DOI":"10.1016\/j.isci.2022.104859","article-title":"Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers","volume":"25","author":"Li","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.stem.2023.02.009_bib258","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.3390\/cancers14112749","article-title":"Targeting immunosuppressive tumor-associated macrophages using innate T\u00a0cells for enhanced antitumor reactivity","volume":"14","author":"Li","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.stem.2023.02.009_bib259","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clim.2010.10.005","article-title":"Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans","volume":"140","author":"Metelitsa","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.stem.2023.02.009_bib260","first-page":"1.19","article-title":"The incredible story of Emily Whitehead\u00a0& CAR T-cell therapy","volume":"44","author":"Neff Newitt","year":"2022","journal-title":"Oncol. Times"},{"key":"10.1016\/j.stem.2023.02.009_bib261","article-title":"Multi-omics characterization of a human stem cell-based model of cardiac hypertrophy","volume":"12","author":"Johansson","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.stem.2023.02.009_bib262","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.stemcr.2022.03.019","article-title":"Functional genomics and the future of iPSCs in disease modeling","volume":"17","author":"Brooks","year":"2022","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.stem.2023.02.009_bib263","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"}],"container-title":["Cell Stem Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193459092300070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193459092300070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:59:09Z","timestamp":1761832749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193459092300070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":263,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S193459092300070X"],"URL":"https:\/\/doi.org\/10.1016\/j.stem.2023.02.009","relation":{},"ISSN":["1934-5909"],"issn-type":[{"value":"1934-5909","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing cell-based cancer immunotherapy through stem cell engineering","name":"articletitle","label":"Article Title"},{"value":"Cell Stem Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.stem.2023.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}